Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 42Stomach Neoplasms 8Neoplasm Metastasis 7Esophageal Neoplasms 7Colorectal Neoplasms 6Neoplasms 5HER2-positive Breast Cancer 5Lung Neoplasms 4Endometrial Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Trastuzumab × 90 days × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡